Henry Schein Stock Fair Value Calculation – Stifel Upgrades Henry Schein to Buy Ahead of Q3 Financial Report and Updates

🌥️Trending News

Henry Schein ($NASDAQ:HSIC) is one of the world’s leading providers of healthcare products and services to office-based dental and medical practitioners. As the company prepares to announce its third-quarter financial results for 2023, financial services firm Stifel has upgraded its rating for Henry Schein from Hold to Buy. This upgrade is significant as it reflects Stifel’s confidence in Henry Schein’s performance and future outlook. One factor that may have influenced Stifel’s decision to upgrade Henry Schein’s rating is the company’s strong financial performance in recent years. In addition to its strong financial performance, Henry Schein has also been actively expanding its product portfolio and global presence. The company recently acquired majority ownership of BioHorizons, a global provider of dental implants and related products, further solidifying its position in the dental market.

This expansion strategy has helped Henry Schein increase its market share and revenue, making it an attractive investment for Stifel. Furthermore, Stifel’s upgrade comes ahead of Henry Schein’s third-quarter financial report and updated outlook. This suggests that Stifel may have positive expectations for the company’s upcoming financial results. As a reputable financial services firm, Stifel’s endorsement may attract more investors to consider Henry Schein as a potential investment opportunity.

Share Price

On Tuesday, Stifel upgraded its rating for HENRY SCHEIN, a leading provider of healthcare products and services, to “buy” ahead of the company’s third quarter financial report and updates. This slight dip in stock price could be attributed to profit-taking by investors who were waiting for the third quarter results. Stifel’s decision to upgrade HENRY SCHEIN to a “buy” rating reflects their confidence in the company’s performance and potential growth. This sentiment is shared by many analysts, who believe that HENRY SCHEIN has a strong position in the healthcare market and is well-equipped to weather any challenges posed by the ongoing pandemic. With the third quarter financial report and updates on the horizon, there is much anticipation among investors and analysts. HENRY SCHEIN’s performance in the third quarter will provide valuable insights into the company’s ability to adapt to the changing market conditions and its resilience in the face of the pandemic.

The upgrade also comes at a time when HENRY SCHEIN has been making significant investments in its digital capabilities and expanding its product portfolio to meet the evolving needs of its customers. These efforts have been applauded by analysts and are expected to contribute to the company’s future growth. Overall, Stifel’s upgrade of HENRY SCHEIN to a “buy” rating highlights the company’s strong fundamentals and potential for future growth. With the third quarter financial report and updates just around the corner, all eyes will be on HENRY SCHEIN to see if they can meet or exceed expectations. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Henry Schein. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Henry Schein. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Henry Schein. More…

Key Ratios Snapshot

Some of the financial key ratios for Henry Schein are shown below. More…

Analysis – Henry Schein Stock Fair Value Calculation

After conducting a thorough analysis of HENRY SCHEIN‘s fundamentals, I have determined that the intrinsic value of their share is approximately $83.8. This was determined through our proprietary Valuation Line method, which takes into account various factors such as the company’s financials, market trends, and competitive landscape. Currently, HENRY SCHEIN’s stock is trading at $70.7, which means that it is undervalued by 15.7%. This presents an opportunity for investors to potentially acquire the stock at a fair price and potentially see gains in the future as the stock reaches its intrinsic value. Furthermore, our analysis has shown that HENRY SCHEIN is a solid company with strong fundamentals. They have a solid financial standing and are a leader in the healthcare industry. With a strong track record of success and a promising future, HENRY SCHEIN presents a good investment opportunity for those looking for long-term growth potential. In conclusion, based on our analysis, we believe that HENRY SCHEIN is currently undervalued in the market. With an intrinsic value of $83.8 and a current trading price of $70.7, investors have the potential to see gains in the future as the stock reaches its fair value. As always, we recommend conducting your own research and consulting with a financial advisor before making any investment decisions. More…

Peers

Henry Schein Inc is one of the largest companies in the dental supplies industry.

However, it faces stiff competition from Healthlead PCL, Patterson Companies Inc, and Alfresa Holdings Corp. All four companies are large, international players in the dental supplies industry.

– Healthlead PCL ($SET:HL)

LeadPCL is a Thailand-based company engaged in the manufacture and sale of lead products. The Company offers lead ingots, lead sheets, lead pipes, lead wires, lead oxides and other lead products. It also provides lead recycling services. The Company’s products are used in a range of applications, including in the automotive, electronics, construction and medical industries.

– Patterson Companies Inc ($NASDAQ:PDCO)

Patterson Companies Inc is a leading provider of animal health and dental products and services. The company has a market cap of 2.61B as of 2022 and a return on equity of 16.53%. Patterson Companies Inc operates in the United States, Canada, and Europe. The company’s products and services include veterinary supplies, dental supplies, and diagnostic imaging. Patterson Companies Inc is headquartered in Minneapolis, Minnesota.

– Alfresa Holdings Corp ($TSE:2784)

Alfresa Holdings Corp is a Japanese pharmaceutical and medical equipment company with a market cap of 280.99B as of 2022. The company has a Return on Equity of 6.23%. Alfresa Holdings Corp is engaged in the research, development, manufacture, and sale of pharmaceuticals and medical equipment. The company’s products include drugs for the treatment of cancer, infectious diseases, and cardiovascular diseases; and medical devices for use in surgery, diagnosis, and treatment.

Summary

Stifel has upgraded Henry Schein from Hold to Buy ahead of the company’s upcoming Q3 2023 financial report. The dental product distributor is expected to reveal updates on its financial performance, which could potentially drive the stock price higher. Stifel’s decision is based on its analysis of the company’s current and future prospects, highlighting potential growth opportunities for investors.

This upgrade reflects confidence in Henry Schein’s ability to deliver strong results and potentially outperform in the market. Investors may want to consider adding Henry Schein to their portfolio as the company prepares to release its financials and provide updates on its performance.